Patient P-01705
Therapy response
Unstable
Tolerance
Stable
GI state
Deteriorating
Inflammatory state
Deteriorating
Nutritional resilience
Unstable
Discontinuation risk
93%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S14
- Day 47 Trajectory diverged from prediction — Observed response fell below the model's expected path.
- Day 49 SC-12 recommended — Supportive Compound SC-12
- Day 50 GI-04 recommended — GI Support Protocol GI-04
- Day 50 Patient declined — Not now
- Day 51 Patient accepted — Started GI-04 in the companion
- Day 59 GI symptom burden −39% vs expected — GI Support Protocol GI-04
- Day 65 Tolerance state changed — Unstable → Improving
- Day 69 ME-01 recommended — Monitoring Escalation ME-01
- Day 70 Patient accepted — Started ME-01 in the companion
- Day 73 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
What changed?
Trajectory began diverging from predicted response on Day 47.
Primary contributors, last 14 days
- GI instability+22
- Nutritional resilience-16
- Inflammatory activity+14
- Treatment adherence-3
- Toxicity+3
What helped?
- Supportive Compound SC-12Day 49Declined by patient
- GI Support Protocol GI-04Day 50Result: symptom burden −39%
- Monitoring Escalation ME-01Day 69Result: deterioration detected before clinical escalation
LIFE OS recommendation
Dietary Support Protocol NP-02
61%
probability of meaningful tolerance improvement
- 284 similar trajectories
- 66% showed improvement
- median effect visible after 10 days
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Inflammatory signalling ↑65
- DNAIL6 -174 variant raises baseline inflammatory tone
- BloodInflammatory load index 54
- WearableHRV 20 ms, trending down
- Butyrate / short-chain fatty acid production ↓55
- MicrobiomeButyrate capacity 25/100
- Daily logFibre intake low in recent food logs
- Mucosal barrier integrity ↓50
- MicrobiomeAkkermansia low → thinner mucus layer
- Daily logGI symptom score 54 and rising
- Autonomic recovery ↓25
- WearableResting HR 81 bpm
- Drug metabolism and exposure ↑20
- BloodToxicity index 43
DNA
Fictional pharmacogenomic panel
- IL6 -174 G/CHigher inflammatory tone
- CYP2D6 Rapid metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 3 · butyrate capacity 25/100
- Akkermansia muciniphilaLow
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisNormal
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 24 ms
- Sleep
- 6.8 h
- Steps
- 7,406
- Resting HR
- 80 bpm
Daily log: GI score 54, nutritional resilience 39, adherence 48.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
- Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
- Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Track each bowel movement today: time, stool form, urgency, overnight waking
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- Electrolyte solution, one sachet after any loose stool
- Fictional demo item: oral nutrition supplement with lunch
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01804 | 23% | S19 | AD-05 | improved | 61 |
| P-01483 | 22% | S14 | AD-05 | no change | 35 |
| P-01679 | 22% | S12 | AD-05 | no change | 39 |
| P-01350 | 22% | S19 | BR-03 | no change | 34 |
| P-01689 | 22% | S13 | BR-03 | no change | 50 |
| P-01696 | 32% | S20 | CR-01 | improved | 59 |
| P-01835 | 32% | S17 | CR-01 | improved | 56 |
| P-01442 | 31% | S13 | CR-01 | improved | 61 |
| P-01371 | 30% | S06 | CR-01 | improved | 63 |
| P-01388 | 30% | S17 | CR-01 | improved | 59 |
| P-01708 | 29% | S07 | CR-01 | improved | 59 |
| P-01877 | 28% | S01 | CR-01 | improved | 67 |